Unique ScFv/antibody highly specific for disease-modified collagen II (found in arthritis patients) has been used to facilitate targeted delivery of therapy to arthritic joints. A fusion construct with mTNFR2-Fc (mouse version of Etanercept) significantly increased efficacy over mTNFR2-Fc alone (p<0.001). Another construct with using viral IL-10 (novel MoA) also provided significant reduction in disease (p=0.0048).
William Harvey Institute
Get in touch with the Business Development Office email@example.com